FDA approves treprostinil dry powder inhaler (Yutrepia) for the treatment of pulmonary arterial hypertension

On May 23, 2025, the biopharmaceutical company Liquidia Corporation announced that the U.S. Food and Drug Administration (FDA) has approved its development of treprostinil dry powder inhaler (treprostinil)-Yutrepia. This innovative therapy is designed to treat pulmonary arterial hypertension (PAH) and pulmonary arterial hypertension associated with interstitial lung disease (PH-ILD) and is designed to improve exercise capacity in adult patients.

Yutrepia is the world's first and only prostacyclin dry powder formulation based on Liquidia's unique PRINT™ technology. The technology produces uniform, free-flowing particles, enabling deep lung delivery in an easy-to-operate, low-power device. The device is designed so that the patient requires less inhalation effort when using it, greatly improving the convenience and comfort of treatment.

Yutrepia's approval was based on results from the Phase 3 INSPIRE trial, which evaluated treprostinil-naive patients and patients who were switched from nebulized treprostinil to Yutrepia. The results of the study showed that Yutrepia performed well in terms of safety and tolerability, and that patients could effectively receive the treatment regardless of whether they had previously used treprostinil.

In Liquidia’s INSPIRE and its extension studies, after more than six years of treating patients, researchers have expressed full confidence in the safety, tolerability and dosage adjustment of Yutrepia. Of particular note is the low-intensity inhalation device used by Yutrepia, which can help patients start and maintain treatment more easily, especially for patients with limited inspiratory flow or lung capacity. This feature is particularly important.

In short,The launch of Yutrepia marks an important development in the field of pulmonary arterial hypertension treatment. It not only provides patients with a new treatment option, but also demonstrates the innovative potential of biopharmaceutical technology. By improving patients' ability to exercise, Yutrepia is expected to improve patients' quality of life and bring new hope to patients facing this rare and serious cardiopulmonary disease.

Reference materials:https://www.drugs.com/pro/yutrepia.html